Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Q1 19/20: Strong sales growth and successful integration of acquisitions

CELLINK publishes the quarterly report for the period 1[st ]of September 2019 – 30[th] of November 2019. The report is available on the company's website: https://cellink.com/investors/ This press release presents a summary of the report. First quarter · Net sales rose to 46,430 kSEK (19,971 kSEK), corresponding to an increase of 132% (148%) compared to the first quarter of the previous financial year, of which 51% (148%) was organic growth. · Operating profit before depreciation and amortization (EBITDA) amounted to -884 kSEK (1,595 kSEK), corresponding to a negative margin (8.

Mangold initiates monitoring of Eurobattery Minerals and sets a target stock price at 106 SEK in a 12 month perspective

Today the independent securities broker Mangold Fondkommission announced that they will start monitoring Eurobattery Minerals (NGM; “BAT”). The company issued an analysis on Eurobattery Minerals that sets a target stock price at 106 SEK in a 12 month period. In the analysis Mangold writes: “Eurobattery Minerals is something as unusual as a green-tech mining company that focuses on producing the necessary metals for the European battery and electric car market, in an environmentally friendly way. Mangold believes that due to the extreme growth of electric cars, tough consumer demands

PowerCell’s Chinese subsidiary receives its first order

PowerCell’s Chinese subsidiary, PowerCell Fuel Cell (Shanghai) Co Ltd, has received an order for a PowerCell S2 fuel cell stack from a new Chinese customer. The order value is insignificant, but the order is the first to be received by the newly started Chinese subsidiary. The stack will be delivered to the customer in February and will be used for testing and validation of PowerCell’s fuel cell technology.PowerCell’s Chines subsidiary PowerCell Fuel Cell Co Ltd, was established in October last year after having received all necessary approvals from the Chinese authorities. The company has

Medivir´s phase II study of MIV-711 in patients with osteoarthritis published in Annals of Internal Medicine

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal Annals of Internal Medicine (DOI: 10.7326/M19-0675). The title of the article is "Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis", author; P.G Conaghan et al. In the same issue there is an editorial by J.N Katz, MD, Msc, with the title; "Structural Modification in Osteoarthritis: Dawn of a New Day", (DOI: 10.7326/M19-3809), where the study results are discussed. Dr. Katz mentions the

CEO update

Dear shareholders, we have had very busy start to the year. Our partner and client dialogues continue in a tireless speed. Our new business development manager has arrived and started meeting customers and has an action plan ahead for creating value. Our plans going forward aiming at changing the data industry have become even clearer and our strategy confirmed by the largest players within the industry. Dialogues with large clients and major partners in order to increase our sell capacity and broaden our revenue streams are ongoing. We are making progress in every meeting conducted. I

Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer

20 January 2020 07:00 GMT   Imfinzi and tremelimumab granted OrphanDrug Designation in the US for liver cancer   AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.   The US Food and Drug Administration (FDA) grants ODD to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

Lynparza regulatory submission granted Priority Review in the US for HRR-mutated metastatic castration-resistant prostate cancer

20 January 2020 07:00 GMT   Lynparza regulatory submission granted Priority Review in the USfor HRR-mutated metastatic castration-resistant prostate cancer   Submission based on PROfound, the first positive Phase III trial testinga targeted treatment in biomarker-selected prostate cancer patients   AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug Application for Lynparza (olaparib) has been accepted and granted Priority Review in the US for patients with metastatic

Notice convening the extraordinary general meeting of AB Electrolux

The shareholders of AB Electrolux, reg. no. 556009-4178, are invited to participate in the Extraordinary General Meeting to be held on Friday, February 21, 2020 at 9 a.m. at AB Electrolux Headquarters, the Axel Wennergren hall, S:t Göransgatan 143, Stockholm, Sweden. Registration to the Extraordinary General Meeting starts at 8.30 a.m.Registration and notification Shareholders who wish to participate in the Extraordinary General Meeting must · be recorded in the share register kept by Euroclear Sweden AB on Saturday, February 15, 2020 (please note that since the record date is on a

Catena takes lead in sustainable gambling with review site focusing on sustainable online casinos

Catena Media starts off the year by launching Playandsustain.com, a site ranking online casinos on how sustainable they are. Play and Sustain will take into consideration four different categories of sustainability of an operator: Carbon FootprintCharitable CausesResponsible GamingCustomer Service“There is no doubt that the last years have seen an increased interest from consumers, investors, employees, governments and operators for CSR initiatives in the gambling industry,” says Johannes Bergh, Deputy CEO Catena Media. “With £14 billion yearly turnover in the UK alone, we expect

Offer to buy back shares in Norwegian Energy Company ASA

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. Norwegian Energy Company ASA ("Noreco" or the "Company") has decided to initiate a share buyback of up to 360,000 shares of the Company in connection with its option program as well as for other corporate purposes. The buyback will be conducted as a reverse book building process at a price to be decided by the Company up to a

Norstedts Juridik CEO gives notice

Olov Sundström, CEO of Norstedts Juridik and Head of the Swedish operations of Karnov Group, has given notice that he has decided to step down and leave the company following the successful completion of the merger between Norstedts Juridik and Karnov Group Sweden.“I have now completed the assignment I got two years ago from the Karnov Group CEO, Flemming Breinholt”, explains Olov Sundström and continues: “I was then asked to lead the integration of Karnov’s Swedish operations with Norstedts Juridik, which Karnov acquired in January 2018. Now we have completed that work and formed one

Outokumpu’s fourth-quarter adjusted EBITDA higher than expected

Outokumpu OyjInside informationJanuary 20, 2020 at 9.00 am EETOutokumpu’s fourth-quarter adjusted EBITDA higher than expected Outokumpu’s fourth-quarter adjusted EBITDA is expected to be approximately EUR 70 million mainly as a result of positive raw material impacts, including improved raw material efficiency and hedging. The company has earlier expected its fourth-quarter adjusted EBITDA to be at a similar level to the third quarter of 2019 (Q3/19: EUR 45 million). Outokumpu will publish the Financial Statements release on February 5, 2020 at approx. 9.00 am EET.   For

Proact reports preliminary figures for the fourth quarter of 2019

Proact today reports preliminary figures for the fourth quarter of 2019 which, like the previous quarter, are characterized by challenges in Business Unit West, including Belgium, the Netherlands and Germany. The improvement plan implemented in Germany in 2019, related to sales challenges, are proceeding as expected and earnings improved compared to the previous quarter.As in the previous quarter, the challenges remain in the Netherlands where lower margins and higher sales costs had an impact on earnings. In Business Unit UK, margins were lower and in Business Units Nordics, earnings

Share buy-backs in Telia Company during week 3 2020

During the period January 13, 2020 until January 17, 2020, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 3,597,874 own shares (ISIN: SE0000667925).The share buy-backs form part of the SEK 5 billion share buy-back program that Telia Company announced on April 16, 2019. The share buy-back program, which runs between April 16, 2019 and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

Africa Energy Operational Update

January 20, 2020 – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, is pleased to provide an operational update on its exploration activities. Garrett Soden, Africa Energy’s President and CEO, commented, “We are excited to begin an extremely active and potentially transformational period for the Company. The Block 11B/12B joint venture operated by Total has embarked on an ambitious exploration program offshore South Africa to follow-up on the large

Diös expands its commercial paper programme

Diös has expanded the maximum size of its commercial paper programme from SEK 2,000 million to SEK 3,500 million and added Danske Bank as a Dealer.-    We have met good demand for our commercial papers, which is why it feels natural to increase the maximum amount and to add another Dealer. The commercial paper programme broadens our funding base, creates opportunities for growth and creates flexibility, says Rolf Larsson, CFO, Diös. The commercial papers are covered by the green financing framework. The programme has a secured back-up facility to manage the refinancing risk. Arranger of

China-Based Ivy Capital Invests in Betagenon's Clinical Stage AMPK Activator Program

Balticgruppen Bio, the Umeå based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round with China based asset management firm Ivy Capital granting the company 3 MUSD of funding. Betagenon has successfully taken its first-in-class PAN-AMPK-activator O304, a novel small molecule for treatment of cardio-metabolic disorders, through pre-clinical and clinical Phase I and Phase IIa testing as well as long-term toxicological studies in animals. The results show that beneficial cardiovascular and metabolic effects

No more long queues for the toilets

Lapee, the female urinal, has just arrived in Australia!!Women can finally skip the endless queues for the traditional toilets at large outdoor events by using Lapee, the first female urinal.  Lapee is designed and produced in Denmark, Europe, where it had its premiere at festivals and sport events in the summer 2019. And wow – what a success! Women just loved it. It is already present in many countries in Europe. We at Lapee are so excited to now introduce the female urinal in Australia for the first time. Lapee will be at Australian Open and at Rainbow Serpent Festival this

ShaMaran to Present at Pareto Securities E&P Independents Conference in London

VANCOUVER, January 17, 2020 /CNW/ - ShaMaran Petroleum Corp. (SNM: TSXV, Nasdaq First North Growth Market) (“ShaMaran” or the “Company”), an oil and gas company with producing assets in the Kurdistan region of Iraq, announces that the Company’s President and CEO, Adel Chaouch, will be presenting at the Pareto Securities E&P Independents Conference in London on January 22, 2020. A copy of the presentation will be available on ShaMaran’s website www.shamaranpetroleum.com and www.thelundingroup.com. OTHER The information was submitted for publication, through the agency of the contact

Brighter is in discussions to acquire Nectarine Health to optimize AI and IoT care solutions

Brighter is in discussions with Nectarine Health’s board and management to acquire the assets of Nectarine Health. EQT Ventures, a shareholder of Nectarine Health has had a long-term interest in assisted care solutions as the aging population and the associated problems form one of the mega trends that needs new solutions. The parties have signed a non-binding Letter of Intent and the parties are now working towards finalizing an agreement during January 2020. Brighter's interest is driven by the opportunity to welcome Nectarine Health’s top of the class AI software and hardware

Board member in MQ sells shares due to private financial reasons

Board member of MQ Holding AB, Bengt Jaller has today sold 2 462 000 shares in MQ, which are 2.3% of the total number of shares in MQ. After the transaction Bengt Jaller owns 600 000 shares in MQ.   Bengt Jaller comments ”Due to private financial reasons I sold shares but I have no intention to sell any further shares. I have a strong faith in the change journey initiated by MQ and look forward to the continued development”. For further information, please contact: Marie Sandahl, IR-chef, +46 (0)31- 388 80 42 This information is information that MQ Holding AB (publ) is obliged

Artificial Solutions Adjusts Guidance for Order Intake for 2019

Artificial Solutions International AB (SSME:ASAI) (“Artificial Solutions” or the “Company”) is adjusting its guidance on one of its reported metrics, Order Intake, for the financial year ending 31[st] Dec 2019. The amended guidance does not affect Revenue, EBITDA or Cashflow, for which all guidance remains unchanged. Despite strong performance in Q2 and Q3 2019, the delay in closing one major contract in Q4 has impacted the full-year Order Intake achievement and the Company now anticipates growth in Order Intake (one of the three financial guidance indicators provided to the market) to be

Publication of Final Terms

Regulatory Announcement Royal Bank of Canada January 17, 2020 Publication of Final Terms Not for release, publication or distribution, directly or indirectly, in or into the United States. Royal Bank of Canada has agreed to issue EUR1,500,000,000 0.01 per cent. Covered Bonds due January 21, 2027, Series CB47 (the "Covered Bonds") pursuant to the €32,000,000,000 Global Covered Bond Programme of Royal Bank of Canada, unconditionally and irrevocably guaranteed as to payments by RBC Covered Bond Guarantor Limited Partnership (the "Programme"). The following document

United Bankers Corporation: Acquisition of Own Shares 17.01.2020

United Bankers Corporation NOTIFICATION 17.01.2020 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 17.01.2020 Date 17.01.2020Exchange transaction BuyShare class UNIAVAmount 443Average price/share 8.9500 EURHighest price/share 8.9500 EURLowest price/share 8.9500 EURTotal price 3,964.85 EUR The shares held by United Bankers Corporation on 17.01.2020: UNIAV 39,964 On behalf of United Bankers CorporationSkandinaviska Enskilda Banken AB (Publ) Antti Salakka

There are no items matching the current filter
There are no more items matching the current filter
Back to top